Previously, in vitro studies had shown that genetically engineering TILs to express IL-2 could prolong their survival after IL-2 withdrawal while maintaining their tumor specificity and function; however, this approach did not yield effective anti-tumor response or lead to prolonged TIL survival in vivo in melanoma patients [74]. Here, IL2 is linked to melanoma.